Lubricant eye drops receive CE Mark

Article

NovaTears has received the CE Mark of approval for the treatment of dry eyes, according to the latest press release from Novaliq.

NovaTears has received the CE Mark of approval for the treatment of dry eyes, according to the latest press release from Novaliq.

The firm developed the drug for use as a topical eye lubricant based on the proprietary technology EyeSoi. NovaTears is a multi-dose, non-aqueous, non-blurring and preservative-free topical eye drop for lubrication of the ocular surface.

Novaliq received a fifth round of financing, with help from Dievini Hopp Bio Tech Holding, raising a total of €13.9 million in April 2013. This funded the ongoing development of its ophthalmic portfolio, including CyclASol Rx as well as additional OTC products.

Bernhard Huenther, CEO of Novaliq, commented, “We are pleased to receive CE mark approval for our first ophthalmic product designed to improve the quality of life for the dry eye OTC patient. It offers a significant new product choice for the European consumer; innovative Novaliq technology that contains no preservatives, yet is available in conventional, multi-dose bottles. The absence of irritating surfactants and preservatives provides dry eye patients improved tolerability and convenience.”

Mathias Hothum, Managing Director of Dievini Hopp Bio Tech Holding, stated, “We congratulate Novaliq on obtaining the CE mark for NovaTears OTC and look forward to future product additions to the SFA portfolio. We are pleased to help Novaliq further its pioneering ocular drug delivery technology and strong management team.”

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.